Cytosorbents Co. (NASDAQ:CTSO) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC boosted its position in shares of Cytosorbents Co. (NASDAQ:CTSO) by 7.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 467,058 shares of the medical research company’s stock after buying an additional 32,415 shares during the quarter. Geode Capital Management LLC’s holdings in Cytosorbents were worth $701,000 at the end of the most recent quarter.

Separately, Sargent Investment Group LLC boosted its stake in Cytosorbents by 13.4% during the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after buying an additional 192,747 shares in the last quarter. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Trading Down 3.3 %

NASDAQ:CTSO opened at $0.94 on Friday. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. Cytosorbents Co. has a 1-year low of $0.70 and a 1-year high of $1.59. The firm has a market capitalization of $51.27 million, a price-to-earnings ratio of -2.60 and a beta of 0.58. The stock has a fifty day simple moving average of $0.92 and a 200 day simple moving average of $1.03.

Analysts Set New Price Targets

Several research analysts recently weighed in on CTSO shares. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a research note on Friday, January 3rd. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a research note on Monday, November 11th. Finally, StockNews.com started coverage on Cytosorbents in a research note on Sunday, January 5th. They set a “hold” rating for the company. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.